Morgan Stanley Galecto, Inc. Transaction History

Morgan Stanley

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Oct 17, 2024	SELL	$0.47 - $0.76 $1,880 - $3,040	-4,001 Reduced 57.15%	3,000 $1,000
Q2 2024 Aug 14, 2024	SELL	$0.47 - $0.76 $1,880 - $3,040	-4,001 Reduced 57.15%	3,000 $1,000
Q1 2024 Oct 17, 2024	BUY	$0.6 - $0.89 $2,400 - $3,560	4,001 Added 133.37%	7,001 $5,000
Q1 2024 Aug 16, 2024	BUY	$0.6 - $0.89 $4,200 - $6,230	7,000 Added 700000.0%	7,001 $5,000
Q1 2024 May 15, 2024	BUY	$0.6 - $0.89 $4,200 - $6,230	7,000 Added 700000.0%	7,001 $5,000
Q4 2023 Aug 16, 2024	SELL	$0.52 - $0.78 $1,559 - $2,339	-2,999 Reduced 99.97%	1 $0
Q3 2023 Nov 15, 2023	BUY	$0.56 - $3.17 $0 - $3	1 New	1 $0
Q2 2022 Aug 15, 2022	SELL	$1.22 - $2.74 $686 - $1,542	-563 Closed	0 $0
Q1 2022 Oct 27, 2022	BUY	$1.72 - $3.31 $968 - $1,863	563 New	563 $1,000
Q1 2022 May 13, 2022	BUY	$1.72 - $3.31 $966 - $1,860	562 Added 56200.0%	563 $1,000
Q4 2021 Feb 14, 2022	BUY	$2.3 - $3.58 $2 - $3	1 New	1 $0

442K

100

100

Ticker GLTO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,395,700
Market Cap $172M
Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.